# INSM catalysts: INSMED Inc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/insm/catalysts

> INSMED Inc (INSM) has 9 upcoming catalysts. The next is the treprostinil palmitil topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | INSMED Inc |
| Ticker | INSM (Nasdaq) |
| SEC CIK | 1104506 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/insm |

## Cash runway

Cash $1.15B as of 2026-09-30; quarterly burn $36.5M; about 94.3 months of runway at that rate (XBRL company facts, accession 0001104506-26-000047).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 28, 2018 | [Arikayce Kit (amikacin sulfate) FDA approval](https://sec-api.dev/pdufa/amikacin) | INSM |  | completed, approved | "NDA207356 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20180928, review_priority PRIORITY; sponsor_name INSMED INC; product ARIKAYCE KIT (AMIKACIN SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207356%22)) |
| October 19, 2020 | [Arikayce Kit (amikacin sulfate) label expansion decision](https://sec-api.dev/pdufa/amikacin) | INSM |  | completed, approved | "NDA207356 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20201019, review_priority STANDARD; sponsor_name INSMED INC; product ARIKAYCE KIT (AMIKACIN SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207356%22)) |
| Sep 2023 | [Azithromycin topline data readout](https://sec-api.dev/pdufa/azithromycin) | INSM |  | completed, positive | "Objective Demonstrate reliability, validity and responsiveness of the PRO/symptom scores Secondary Objective Demonstrate effect of ARIKAYCE on culture conversion, time to culture conversion 200-220 sites across ARISE and ENCORE Topline results from Phase 3 ENCORE trial expected in Q1:26 Aligned on Primary Endpoint (PE) with FDA (8 questions from QoL-B) ENCORE enrollment of 425 patients (>90% powering on PE) Positive topline results from Phase 3 ARISE trial shared in September 2023 *Azithromycin (AZI), Ethambutol (ETH) ARIKAYCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-2.htm)) |
| Mar 2024 | [XHANCE (xhance) FDA approval](https://sec-api.dev/pdufa/xhance) | INSM |  | completed, approved | "XHANCE® received FDA approval in March 2024. \| ** Includes data from all participants in the trial (including those on placebo) that completed the 24-week study at the time of analysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-2.htm)) |
| May 2024 | [INSMED Inc topline data readout](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed, positive | "In May 2024, we reported positive topline safety data and certain exploratory efficacy endpoints from the Phase 2a study of TPIP in patients with PH-ILD." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000032/insm-20260331.htm)) |
| Dec 2024 | [BRINSUPRI® (brensocatib) NDA/BLA submission](https://sec-api.dev/pdufa/brensocatib) | INSM | bronchiectasis with the U | completed | "Insmed submitted a new drug application (NDA) for brensocatib for patients with bronchiectasis with the U.S. Food and Drug Administration (FDA) in December 2024 and is currently awaiting FDA acceptance of that submission." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-1.htm)) |
| Dec 2024 | [BRINSUPRI® (brensocatib) trial start](https://sec-api.dev/pdufa/brensocatib) | INSM |  | completed | "•We initiated a Phase 2b study of brensocatib in patients with HS, which we refer to as the CEDAR trial, in December 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1104506/000110450625000043/insm-20250630.htm)) |
| Q1 2025 | [BRINSUPRI® (brensocatib) PDUFA date](https://sec-api.dev/pdufa/brensocatib) | INSM |  | scheduled | "First-Quarter 2025 Highlights * Pending regulatory approval for bronchiectasis indication \| FDA: Food and Drug Administration \| PDUFA: Prescription Drug User Fee Act Mid- to late-stage programs refers to all clinical programs in Phase 2 and Phase 3 Double-digit ARIKAYCE growth All mid- to late-stage clinical programs on or ahead of schedule FDA review of brensocatib undisrupted PDUFA target action date of Aug. 12th for potential U.S. approval of brensocatib*" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-2.htm)) |
| February 6, 2025 | [BRINSUPRI® (brensocatib) NDA/BLA acceptance](https://sec-api.dev/pdufa/brensocatib) | INSM | bronchiectasis | completed | "On February 6, 2025, the Company issued a press release announcing that the FDA has accepted for review the Company's NDA for brensocatib for patients with non-cystic fibrosis bronchiectasis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036125003266/ef20043003_8k.htm)) |
| February 18, 2025 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-1.htm)) |
| mid-2025 | [INS1201 topline data readout](https://sec-api.dev/pdufa/ins1201) | INSM | PAH Completed in December 2024 | scheduled | "—Enrollment for Phase 2 Study of TPIP in Patients with PAH Completed in December 2024; Expected Timing for Topline Data Moved Forward to Mid-2025—" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-1.htm)) |
| May 8, 2025 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm)) |
| Jun 2025 | [INS1201 topline data readout](https://sec-api.dev/pdufa/ins1201) | INSM | PAH Completed | completed, positive | "Insmed reported positive topline data from the Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) in June 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm)) |
| June 10, 2025 | [INSMED Inc topline data readout](https://sec-api.dev/companies/insm/catalysts) | INSM | pulmonary arterial hypertension | completed, positive | "On June 10, 2025, the Company announced positive topline results from its Phase 2b TPIP PAH study, a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of TPIP administered once daily in patients with PAH (World Health" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036125022023/ef20050418_8k.htm)) |
| Jul 2025 | [INS1201 trial start](https://sec-api.dev/pdufa/ins1201) | INSM | Duchenne muscular dystrophy | completed | "Insmed dosed the first patient in the Phase 1 ASCEND clinical study of INS1201, an intrathecally-delivered gene therapy for patients with Duchenne muscular dystrophy (DMD), in July 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm)) |
| August 7, 2025 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm)) |
| August 12, 2025 | [INS1201 PDUFA date](https://sec-api.dev/pdufa/ins1201) | INSM |  | scheduled | "Prescription Drug User Fee Act (PDUFA) target action date of August 12, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm)) |
| August 12, 2025 | [BRINSUPRI® (brensocatib) FDA approval](https://sec-api.dev/pdufa/brensocatib) | INSM | To treat non-cystic fibrosis bronchiectasis | completed, approved | "Brinsupri \| brensocatib \| 8/12/2025 \| To treat non-cystic fibrosis bronchiectasisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| August 12, 2025 | [BRINSUPRI® (brensocatib) PDUFA date](https://sec-api.dev/pdufa/brensocatib) | INSM | Bronchiectasis Remains | completed, approved | "The FDA had previously granted Priority Review to Insmed's NDA for brensocatib and set a target action date of August 12, 2025, under the Prescription" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125005570/ef20044166_ex99-1.htm)) |
| late 2025 | [BRINSUPRI® (brensocatib) topline data readout](https://sec-api.dev/pdufa/brensocatib) | INSM | CRSsNP | delayed | "Insmed continues to anticipate topline data from the study in the middle of 2025, ahead of the anticipated U.S. launch of brensocatib." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-1.htm)) |
| September 30, 2025 | [BRINSUPRI® (brensocatib) primary completion](https://sec-api.dev/pdufa/brensocatib) | INSM | Chronic Rhinosinusitis Without Nasal Polyps | completed | "NCT06013241 (A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06013241)) |
| Q4 2025 | [BRINSUPRI® (brensocatib) trial start](https://sec-api.dev/pdufa/brensocatib) | INSM | pulmonary hypertension associated with interstitial lung disease | scheduled | "—PALM-ILD Phase 3 Study of TPIP for PH-ILD Expected to Initiate in the Fourth Quarter of 2025; Additional Phase 3 Studies Planned for PAH, PPF, and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm)) |
| October 30, 2025 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm)) |
| November 21, 2025 | [Alis primary completion](https://sec-api.dev/pdufa/alis) | INSM | Mycobacterium Infections, Nontuberculous | completed | "NCT04677569 (Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04677569)) |
| Jan 2026 | [BRINSUPRI® (brensocatib) topline data readout](https://sec-api.dev/pdufa/brensocatib) | INSM | CRSsNP | delayed | "—Topline Data Readout Anticipated for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP by Early January 2026—" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm)) |
| early 2026 | [INS1201 trial start](https://sec-api.dev/pdufa/ins1201) | INSM | PAH in early 2026 | scheduled | "The Company plans to initiate a Phase 3 study of TPIP in patients with PAH in early 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm)) |
| Q1 2026 | [INS1201 topline data readout](https://sec-api.dev/pdufa/ins1201) | INSM | Newly Diagnosed or Recurrent MAC Lung Disease Fully Enrolled | scheduled | "The Company continues to anticipate a topline readout for ENCORE in the first quarter of 2026, with the submission of a supplementary new drug application (sNDA) to the FDA for ARIKAYCE in all patients with MAC lung disease in the U.S. expected later in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-1.htm)) |
| Q1 2026 | [INSMED Inc topline data readout](https://sec-api.dev/companies/insm/catalysts) | INSM |  | scheduled | "•We anticipate reporting topline data from the ENCORE trial in the first quarter of 2026, with the submission of a US supplementary new drug application for ARIKAYCE in all patients with MAC lung disease projected for late 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1104506/000110450625000009/insm-20241231.htm)) |
| Jan 2026 | [INS1202 trial start](https://sec-api.dev/pdufa/ins1202) | INSM | amyotrophic lateral sclerosis | completed | "In January 2026, the Company dosed the first patient in the Phase 1 ARMOR study of INS1202, an intrathecally delivered gene therapy for patients with amyotrophic lateral sclerosis (ALS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_ex99-1.htm)) |
| February 12, 2026 | [BRINSUPRI® (brensocatib) primary completion](https://sec-api.dev/pdufa/brensocatib) | INSM | Hidradenitis Suppurativa | withdrawn | "NCT06685835 (A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685835)) |
| February 17, 2026 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_ex99-1.htm)) |
| Mar 2026 | [INSMED Inc topline data readout](https://sec-api.dev/companies/insm/catalysts) | INSM | Mycobacterium avium complex | completed, met | "In March 2026, Insmed reported positive topline results from the Phase 3b ENCORE study of ARIKAYCE in patients with Mycobacterium avium complex (MAC) lung disease, which met its primary and all multiplicity-controlled secondary culture conversion endpoints." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/ef20072589_ex99-1.htm)) |
| Mar 2026 | [INSMED Inc topline data readout](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed, positive | "We announced positive topline results from the ENCORE study in March 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000032/insm-20260331.htm)) |
| March 23, 2026 | [Azithromycin topline data readout](https://sec-api.dev/pdufa/azithromycin) | INSM |  | completed, positive | "BRIDGEWATER, N.J., Mar. 23, 2026 -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced positive topline results from the Phase 3b ENCORE study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126010651/ef20068516_ex99-1.htm)) |
| Q2 2026 | [BRINSUPRI® (brensocatib) topline data readout](https://sec-api.dev/pdufa/brensocatib) | INSM | HS Now | scheduled | "Insmed anticipates reporting topline data from CEDAR in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_ex99-1.htm)) |
| Apr 2026 | [INSMED Inc topline data readout](https://sec-api.dev/companies/insm/catalysts) | INSM |  | scheduled | "•We anticipate reporting topline data from the ENCORE trial by April 2026, with the submission of a US supplementary new drug application (sNDA) for ARIKAYCE in all patients with MAC lung disease projected for the second half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm)) |
| Apr 2026 | [INSMED Inc topline data readout](https://sec-api.dev/companies/insm/catalysts) | INSM | newly diagnosed or recurrent Mycobacterium avium complex | scheduled | "In March or April of 2026, the Company anticipates the topline readout of the Phase 3 ENCORE trial in patients with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease who have not started antibiotics." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_ex99-1.htm)) |
| April 1, 2026 | [Treprostinil palmitil inhalation powder primary completion](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Pulmonary Hypertension; Interstitial Lung Disease | completed | "NCT05649722 (An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-04-01 (ACTUAL); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05649722)) |
| May 7, 2026 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/ef20072589_ex99-1.htm)) |
| Q3 2026 | [INS1033 trial start](https://sec-api.dev/pdufa/ins1033) | INSM |  | scheduled | "Insmed plans to initiate a Phase 1 trial in healthy volunteers in the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm)) |
| 2H 2026 | [BRINSUPRI® (brensocatib) trial start](https://sec-api.dev/pdufa/brensocatib) | INSM |  | scheduled | "The Company anticipates initiating additional Phase 3 studies of TPIP in progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm)) |
| Jul 2026 | [INSMED Inc NDA/BLA submission](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "In July 2026, Insmed submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for ARIKAYCE in newly diagnosed patients with MAC lung disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm)) |
| August 6, 2026 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm)) |
| Sep 2026 | [INSMED Inc NDA/BLA acceptance](https://sec-api.dev/companies/insm/catalysts) | INSM | Mycobacterium avium complex | completed | "In September 2026, the U.S. Food and Drug Administration (FDA) accepted Insmed's Supplemental New Drug Application (sNDA) for review of ARIKAYCE for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_ex99-1.htm)) |
| October 29, 2026 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_ex99-1.htm)) |
| Dec 2026 to Mar 2027 | [Treprostinil palmitil topline data readout](https://sec-api.dev/pdufa/treprostinil-palmitil) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT05649748 (An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05649748)) |
| December 2026 | [Treprostinil palmitil primary completion](https://sec-api.dev/pdufa/treprostinil-palmitil) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT05649748 (An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05649748)) |
| January 28, 2027 | [INSMED Inc PDUFA date](https://sec-api.dev/companies/insm/catalysts) | INSM | MAC lung disease | scheduled | "Revenue† U.S. $75.5M +2% Int'l $48.9M +21% Worldwide $124.4M +9% sNDA granted priority review by FDA, with PDUFA target action date of January 28, 2027 Intend to submit data to PMDA in Q4:26 to support potential Japan label expansion Expect to launch under expanded all MACLD label in the U.S. & Japan in 1H:27* Combined TAM could expand to >200K patients‡ in the U.S. and Japan*" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_ex99-2.htm)) |
| Dec 2028 to Mar 2029 | [Treprostinil palmitil inhalation powder topline data readout](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Pulmonary Hypertension; Interstitial Lung Disease | scheduled | "NCT07179380 (Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07179380)) |
| Dec 2028 to Mar 2029 | [Treprostinil palmitil inhalation powder topline data readout](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT07481981 (A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-28 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07481981)) |
| December 2028 | [Treprostinil palmitil inhalation powder primary completion](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT07481981 (A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-28 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07481981)) |
| December 2028 | [Treprostinil palmitil inhalation powder primary completion](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Pulmonary Hypertension; Interstitial Lung Disease | scheduled | "NCT07179380 (Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07179380)) |
| Aug to Nov 2030 | [Treprostinil palmitil inhalation powder topline data readout](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Progressive Pulmonary Fibrosis; Interstitial Lung Disease | scheduled | "NCT07805785 (A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-31 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07805785)) |
| August 2030 | [Treprostinil palmitil inhalation powder primary completion](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Progressive Pulmonary Fibrosis; Interstitial Lung Disease | scheduled | "NCT07805785 (A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-31 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07805785)) |

## Drugs

- [Alis](https://sec-api.dev/pdufa/alis): Mycobacterium Infections, Nontuberculous
- [Arikayce Kit (amikacin sulfate)](https://sec-api.dev/pdufa/amikacin): 
- [Azithromycin](https://sec-api.dev/pdufa/azithromycin): 
- [BRINSUPRI® (brensocatib)](https://sec-api.dev/pdufa/brensocatib): crssnp, bronchiectasis, non-cystic fibrosis bronchiectasis, chronic rhinosinusitis without nasal polyps, bronchiectasis remains, To treat non-cystic fibrosis bronchiectasis, Hidradenitis Suppurativa
- [INS1033](https://sec-api.dev/pdufa/ins1033): 
- [INS1201](https://sec-api.dev/pdufa/ins1201): pulmonary hypertension associated with interstitial lung disease, newly diagnosed or recurrent mycobacterium avium complex, pah in early 2026, duchenne muscular dystrophy, pah completed, pah completed in december 2024
- [INS1202](https://sec-api.dev/pdufa/ins1202): amyotrophic lateral sclerosis
- [Treprostinil palmitil](https://sec-api.dev/pdufa/treprostinil-palmitil): Pulmonary Arterial Hypertension
- [Treprostinil palmitil inhalation powder](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder): Pulmonary Hypertension, Pulmonary Arterial Hypertension, Progressive Pulmonary Fibrosis
- [XHANCE (xhance)](https://sec-api.dev/pdufa/xhance): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/insm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INSM catalysts: INSMED Inc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/insm/catalysts

```bibtex
@misc{secapidev_companies_insm_catalysts_20261116,
  title        = {INSM catalysts: INSMED Inc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/insm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_insm_catalysts_20261116","title":"INSM catalysts: INSMED Inc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/insm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
